A bio-technology pharma company from Zurich, Switzerland has developed a drug that can reduce high blood pressure for several months at a time.
The drug cleans up 'angiotensin II', a natural peptide that raises blood pressure by contracting vessels, by inducing antibodies.
In the trial that involved 72 people, drug CYT006-AngQb developed by Cytos Biotechnology reduced systolic blood pressure by 25 millimetres of mercury as compared to placebo treatment.
The drug also lowered diastolic pressure went down by 13 mmHg.
"We can certainly reduce blood pressure, but whether it's enough to be clinically meaningful we can't say yet," New Scientist quoted Martin Bachmann of Cytos, as saying.
"Four months after the shot, only half of the antibodies were left, so people may need a top-up every six months," Bachmann added.